Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
+$0.02 today
- Market cap
- $546.27M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
Volume 0.87M
Average 0.88M
CLYM Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Climb Bio, Inc.NASDAQ: CLYM
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $13.72M (cash outflow) fell 34.0% year over year, ahead of the -43.2% change in trailing-twelve-month net income. Sequentially, it fell 21.7% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -$62.93M (+5.1%) for the fiscal year ending Dec 2026, a step up from the -19.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.72M-21.7% QoQ
- Last fiscal yearDec 2025
- -$59.85M-19.0% YoY
- LTMMar 2026
- -$52.79M-43.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -34.0% | +69.4% | +103.4 pp |
| 1 year | -19.0% | +5.1% | +24.2 pp |
| 3-year CAGR | +9.8% | +30.0% | +20.2 pp |
| 5-year CAGR | +17.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (59.85M) USD
- Year-over-year change
- +19.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (59.85M) | +19.0% |
| FY2024 | 2024-12-31 | (73.9M) | -110.4% |
| FY2023 | 2023-12-31 | (35.12M) | +22.4% |
| FY2022 | 2022-12-31 | (45.24M) | +4.7% |
| FY2021 | 2021-12-31 | (47.48M) | — |
Net Income vs competitors
How CLYM compares with its peers on the latest reported figures
- CLYM's LTM Mar 2026 net income of $52.79M is the smallest of the 5 companies compared; the peer median is $161.43M.
- Its year-over-year change of -43.2% is the lowest of 5, against a peer median of +68.2%.
- Over three fiscal years its annual growth of +9.8% compares with a peer median of +46.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $175.43M | +38.4% | +46.9% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $166.09M | +1.5% | — | — |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $156.76M | +98.0% | +81.8% | 4719.0% |
| LTM Mar 2026 | $78.15M | +141.3% | -19.7% | — | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $52.79M | -43.2% | +9.8% | — |
| Peer median (excluding CLYM) | $161.43M | +68.2% | +46.9% | 4719.0% | |
Competitors are the stored peer set for CLYM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47.48M) | (45.24M) | (35.12M) | (73.9M) | (59.85M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 97K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.74M | 6.99M | 12.81M | 5.56M | 8.05M |
| Change in Working Capital | (4.17M) | 210K | 3.76M | 1.7M | (601K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 318K | (653K) | (686K) | (1.14M) | 1.56M |
| Other Working Capital | (4.49M) | 863K | 4.45M | 2.84M | (2.17M) |
| Other Non-Cash Items | 11.84M | 674K | (2.05M) | 51.08M | (2.06M) |
| Operating Cash Flow | (36.07M) | (37.37M) | (20.6M) | (15.56M) | (54.36M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (186K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (114.97M) | (87.96M) | (58.45M) | (132.2M) | (108.08M) |
| Sales of Investments | 0 | 122.4M | 127.43M | 20.75M | 111.1M |
| Other Investing Activities | 0 | 0 | 0 | (9.65M) | 0 |
| Investing Cash Flow | (114.97M) | 34.44M | 68.98M | (121.09M) | 2.83M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 83.14M | 0 | 841K | 119.75M | (21K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 149K | 0 | 0 | 10.98M | 0 |
| Financing Cash Flow | 177.23M | 0 | 841K | 130.73M | (21K) |
| Effect of Forex Changes | 245K | (408K) | 304K | 42K | 0 |
| Net Change in Cash | 26.44M | (3.34M) | 49.53M | (5.88M) | (51.54M) |
| Free Cash Flow | (36.07M) | (37.37M) | (20.6M) | (15.56M) | (54.54M) |
Climb Bio, Inc.
NASDAQ:CLYM
Intrinsic Alpha fair value
Locked
Current Price
$9.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.